SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories trades higher on the bourses

20 Jun 2013 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 355.10, up by 0.95 points or 0.27% from its previous closing of Rs. 354.15 on the BSE.

The scrip opened at Rs. 350.00 and has touched a high and low of Rs. 356.70 and Rs. 349.00 respectively. So far 112828 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 578.30 on 04-Sep-2012 and a 52 week low of Rs. 342.75 on 18-Jun-2013.

Last one week high and low of the scrip stood at Rs. 386.50 and Rs. 342.75 respectively. The current market cap of the company is Rs. 14998.93 crore.

The promoters holding in the company stood at 63.52% while Institutions and Non-Institutions held 20.58% and 13.80% respectively.

Ranbaxy Laboratories is disappointed with the Decision by the European Commission to rule its patent settlement agreement with Lundbeck, covering the molecule Citalopram, anti-competitive, and intends to appeal the Decision to the General Court of the European Union (EU). These events took place over ten years ago, and the company considers that the Commission has misunderstood the facts and misapplied the law. The company  believes it has strong grounds of appeal. Ranbaxy respects, and is committed to conducting its business in compliance with, European law, and is dedicated to offering high quality, affordable medicines for the benefit of patients, prescribers, customers and the European healthcare system.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×